A new method for growing tumor-infiltrating lymphocytes (TILs) without using donor feeder cells may make advanced cancer immunotherapy safer and more reliable. The system, described in a recent report, eliminates the need for irradiated allogeneic feeder cells that have been a standard part of the TIL expansion process. This change could reduce contamination risks and simplify the manufacturing of personalized cell therapies for people with advanced cancers.

Key takeaways

  • Traditional TIL expansion uses donor feeder cells, which can introduce variability and safety concerns.
  • The new feeder-free system grows TILs using a specialized culture method without foreign cells.
  • This approach may lower the risk of contamination and make the therapy easier to produce.
  • Early results suggest the feeder-free TILs retain their anti-tumor activity.

What is TIL therapy and why does feeder cell use matter?

Tumor-infiltrating lymphocyte therapy is a type of adoptive cell transfer. Doctors remove immune cells that have already entered a patient’s tumor, grow them in large numbers in a lab, and then infuse them back into the patient. These expanded TILs can recognize and attack cancer cells. The process typically requires feeder cells, often irradiated donor blood cells, to help stimulate TIL growth. However, using feeder cells adds complexity, cost, and potential safety issues such as contamination or immune reactions.

How the feeder-free system works

The new system replaces feeder cells with a carefully designed culture environment. According to the original report, researchers developed a method that provides the necessary growth signals without relying on donor cells. The approach uses specific cytokines and culture conditions that mimic the support feeder cells normally provide. The resulting TILs grow efficiently and maintain their ability to target tumor cells.

Potential benefits for patients and manufacturing

Eliminating feeder cells could simplify the manufacturing process for TIL therapy. It removes the need to source, irradiate, and test donor cells. This may reduce production time and cost. For patients, a feeder-free system could lower the risk of contamination with pathogens or foreign proteins. It may also allow more consistent product quality from batch to batch. The report notes that the feeder-free TILs showed comparable anti-tumor activity to traditionally expanded cells in early testing.

Challenges and next steps

While the feeder-free system shows promise, it is still in early development. Researchers need to confirm these results in larger studies and in clinical settings. The system must prove it can reliably produce enough TILs for treatment across different cancer types. Regulatory approval will also require demonstrating safety and effectiveness compared to existing methods. The original report describes this as a step toward more accessible and safer TIL therapy.

Frequently Asked Questions

What are feeder cells in TIL therapy?

Feeder cells are donor cells, often irradiated blood cells, that are added to TIL cultures to help the immune cells grow. They provide growth factors and support signals. However, they also introduce risks of contamination and variability.

Is feeder-free TIL therapy available now?

The feeder-free system is still in research stages. It has not yet been approved for routine clinical use. Further studies and regulatory reviews are needed before it becomes widely available.

Does feeder-free expansion affect TIL effectiveness?

Early data from the report suggests that feeder-free TILs maintain their ability to recognize and kill tumor cells. More research is needed to confirm this in patients and across different cancer types.

This is an original report by Vital Signs Today, informed by reporting from Google News. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.